AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention. - Wikidata - awgldk - TriplyDB

AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.

AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.

http://www.wikidata.org/entity/Q37340445

about

Advances in aluminum hydroxide-based adjuvant research and its mechanism Recombinant lipidated HPV E7 induces a Th-1-biased immune response and protective immunity against cervical cancer in a mouse model.Modern Medicine: Towards Prevention, Cure, Well-being and Longevity.Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles.Educational interventions to increase HPV vaccination acceptance: a systematic review.Comparative Transcriptome Profiles of Human Blood in Response to the Toll-like Receptor 4 Ligands Lipopolysaccharide and Monophosphoryl Lipid A.Perspectives for the development of human papillomavirus vaccines and immunotherapy.Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.Age-Specific Adjuvant Synergy: Dual TLR7/8 and Mincle Activation of Human Newborn Dendritic Cells Enables Th1 Polarization.

P2860

Q27007659-20E2C6E1-9E02-4D17-B601-61BB89CB7E01 Q34345467-A0D6C788-75B3-444B-906F-F824DEAA6656 Q34543958-02FEAF83-CAE7-4CDE-86BE-0C19704EC15B Q34600988-A065DE2E-5B23-4DA0-990D-36CFC966FA4A Q34846745-689CE071-B6B4-4028-94C4-32F42386F9E7 Q37560510-8F567200-2743-4439-A0F2-DFA475504850 Q37658876-29511CC6-1612-42EC-82CD-99858FC8429F Q37867102-09C330EB-5CCA-438A-86D5-151CCE7C6707 Q40468799-2C91ECCD-1C49-4DE1-A5E4-76DC820094FD

P2860

AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.

http://www.wikidata.org/entity/Q37340445

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

AS04-adjuvanted human papillom ...... in cervical cancer prevention.

@en

AS04-adjuvanted human papillom ...... in cervical cancer prevention.

@nl

type

label

AS04-adjuvanted human papillom ...... in cervical cancer prevention.

@en

AS04-adjuvanted human papillom ...... in cervical cancer prevention.

@nl

prefLabel

AS04-adjuvanted human papillom ...... in cervical cancer prevention.

@en

AS04-adjuvanted human papillom ...... in cervical cancer prevention.

@nl

P1433

Q37340445-32569F33-FEE1-4102-A390-AE13B15EA230

P1476

Q37340445-898335ED-B907-4EED-888B-AE13114A2F1F

P2093

Q37340445-39DE1182-6CDB-4357-A360-7B484CDB7BCE

P2860

Q37340445-01143304-25EB-4E30-AE5F-5AB23888DE12

Q37340445-050D65A4-34FB-4C0E-BC4C-43A15874F523

Q37340445-064CBAD1-B08A-4FC4-94CD-89946E6C24B4

Q37340445-0C247AD4-095D-418F-8381-2BA49CB89FF4

Q37340445-159E847D-C0CF-4D53-990F-26719672AC09

Q37340445-1EBA5084-1CD8-4E47-8282-F301B1FCD471

Q37340445-2369B296-2671-4D2F-986D-CCA5477B6FAA

Q37340445-2720AFCA-A000-49A8-A7CB-37A1FFDD97E5

Q37340445-2B8B9C68-4A27-4562-9F95-1B64E41C4218

Q37340445-325D2A3F-C592-495E-BD6C-43D35EE20258

P304

Q37340445-C50F9759-5DCA-4D6A-AA26-187E6F063856

P31

Q37340445-ABD30D4D-3F16-4B75-B147-E30356F140C3

P356

Q37340445-2EF425C2-2AC6-4CB4-9ECF-5359B76D9177

P433

Q37340445-605A04A0-CDD9-421A-B2EF-72F51882C6EC

P478

Q37340445-C54EFF5E-ACA9-4FE0-A8DF-68863C018D9B

P577

Q37340445-E2E4CD7C-8557-4298-9601-7D16251AF663

P698

Q37340445-0E738446-04ED-4957-B4A6-D9B229C1F62C

P356

14760584.7.10.1465

P1433

Expert Review of Vaccines

P1476

AS04-adjuvanted human papillom ...... in cervical cancer prevention.

@en

P2093

Tino F Schwarz

http://www.w3.org/2001/XMLSchema#string

P2860

The causal relation between human papillomavirus and cervical cancer.

Global cancer statistics, 2002

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

Epidemiologic classification of human papillomavirus types associated with cervical cancer

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

Classification of papillomaviruses

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.

The epidemiology of human papillomavirus infections.

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.

P304

1465-1473

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14760584.7.10.1465

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19053203

http://www.w3.org/2001/XMLSchema#string